FDA to review Neoprobes RIGS technology
Neoprobe, a developer of oncology surgical and diagnostic products, has been granted a Type B meeting with the FDA regarding its investigational new drug application for its RIGS technology biologic license application.

The company said RIGS technology involves the use of a radiolabeled tumor-specific targeting agent to alert surgeons to the existence of cancerous tissue, undetectable by traditional diagnostic and intraoperative techniques.

The RIGS procedure may enable more effective colorectal cancer surgeries leading to improved patient treatment, said Dublin, Ohio-based Neoprobe.